Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2510-3636
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Clinical experience with 18F-JK-PSMA-7 when using a digital PET/CT ; volume:6 ; number:1 ; day:15 ; month:3 ; year:2022 ; pages:1-10 ; date:12.2022
European journal of hybrid imaging ; 6, Heft 1 (15.3.2022), 1-10, 12.2022

Creator
Vierasu, Irina
Trotta, Nicola
Albisinni, Simone
Mathey, Céline
Leurquin-Sterk, Gil
Lacroix, Simon
Simaeys, Gaetan Van
Quackels, Thierry
Roumeguère, Thierry
Goldman, Serge
Contributor
SpringerLink (Online service)

DOI
10.1186/s41824-022-00128-3
URN
urn:nbn:de:101:1-2022052019382580493354
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Vierasu, Irina
  • Trotta, Nicola
  • Albisinni, Simone
  • Mathey, Céline
  • Leurquin-Sterk, Gil
  • Lacroix, Simon
  • Simaeys, Gaetan Van
  • Quackels, Thierry
  • Roumeguère, Thierry
  • Goldman, Serge
  • SpringerLink (Online service)

Other Objects (12)

[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma

Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

18F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study

18F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis

Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis

Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer

Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer

Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer

Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer

Related objects